Bone drug lowers breast cancer risk 38% in high-risk women
April 20, 2010
USA Today
A common osteoporosis drug, raloxifene, reduces
breast cancer risk by 38% in women at high risk for the disease,
without causing the serious side effects of similar drugs, a new study
shows.
That suggests more high-risk women should
consider taking raloxifene, also known as Evista, says Victor Vogel,
main author of the study presented Monday at the American
Association for Cancer Research meeting in Washington... read more
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
